Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.47
ACOR's Cash to Debt is ranked lower than
74% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. ACOR: 1.47 )
Ranked among companies with meaningful Cash to Debt only.
ACOR' s Cash to Debt Range Over the Past 10 Years
Min: 1.03  Med: 30.31 Max: N/A
Current: 1.47
Equity to Asset 0.57
ACOR's Equity to Asset is ranked lower than
63% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ACOR: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
ACOR' s Equity to Asset Range Over the Past 10 Years
Min: -3.98  Med: 0.53 Max: 0.75
Current: 0.57
-3.98
0.75
Interest Coverage 1.19
ACOR's Interest Coverage is ranked lower than
95% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACOR: 1.19 )
Ranked among companies with meaningful Interest Coverage only.
ACOR' s Interest Coverage Range Over the Past 10 Years
Min: 2.2  Med: 9.82 Max: 13.99
Current: 1.19
2.2
13.99
F-Score: 6
Z-Score: 2.01
M-Score: -2.40
WACC vs ROIC
8.91%
11.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 3.55
ACOR's Operating margin (%) is ranked higher than
73% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. ACOR: 3.55 )
Ranked among companies with meaningful Operating margin (%) only.
ACOR' s Operating margin (%) Range Over the Past 10 Years
Min: -153.55  Med: 1.25 Max: 12
Current: 3.55
-153.55
12
Net-margin (%) 2.68
ACOR's Net-margin (%) is ranked higher than
72% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. ACOR: 2.68 )
Ranked among companies with meaningful Net-margin (%) only.
ACOR' s Net-margin (%) Range Over the Past 10 Years
Min: -155.44  Med: -1.96 Max: 50.67
Current: 2.68
-155.44
50.67
ROE (%) 2.29
ACOR's ROE (%) is ranked higher than
77% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. ACOR: 2.29 )
Ranked among companies with meaningful ROE (%) only.
ACOR' s ROE (%) Range Over the Past 10 Years
Min: -92.5  Med: 1.93 Max: 52.43
Current: 2.29
-92.5
52.43
ROA (%) 1.21
ACOR's ROA (%) is ranked higher than
78% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. ACOR: 1.21 )
Ranked among companies with meaningful ROA (%) only.
ACOR' s ROA (%) Range Over the Past 10 Years
Min: -40.61  Med: -1.28 Max: 32.8
Current: 1.21
-40.61
32.8
ROC (Joel Greenblatt) (%) 56.26
ACOR's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ACOR: 56.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACOR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4354.61  Med: -128.76 Max: 1008.02
Current: 56.26
-4354.61
1008.02
Revenue Growth (3Y)(%) 14.20
ACOR's Revenue Growth (3Y)(%) is ranked higher than
68% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ACOR: 14.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACOR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.8  Med: 11.60 Max: 73.6
Current: 14.2
-61.8
73.6
EBITDA Growth (3Y)(%) 14.40
ACOR's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ACOR: 14.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACOR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -80.8  Med: -57.10 Max: 17.8
Current: 14.4
-80.8
17.8
EPS Growth (3Y)(%) -59.60
ACOR's EPS Growth (3Y)(%) is ranked lower than
95% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. ACOR: -59.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACOR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -84  Med: -59.60 Max: -12.3
Current: -59.6
-84
-12.3
» ACOR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ACOR Guru Trades in Q2 2015

Paul Tudor Jones Sold Out
Jim Simons 284,300 sh (-10.88%)
John Hussman 136,000 sh (-35.24%)
» More
Q3 2015

ACOR Guru Trades in Q3 2015

Steven Cohen 1,082,719 sh (New)
Jim Simons Sold Out
John Hussman 55,000 sh (-59.56%)
» More
Q4 2015

ACOR Guru Trades in Q4 2015

Jim Simons 175,900 sh (New)
John Hussman 100,000 sh (+81.82%)
Steven Cohen 151,400 sh (-86.02%)
» More
Q1 2016

ACOR Guru Trades in Q1 2016

Joel Greenblatt 28,514 sh (New)
Paul Tudor Jones 24,615 sh (New)
John Hussman 250,000 sh (+150.00%)
Steven Cohen 60,900 sh (-59.78%)
Jim Simons 61,600 sh (-64.98%)
» More
» Details

Insider Trades

Latest Guru Trades with ACOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:AXON, NAS:INVA, NYSE:EBS, OTCPK:SXMDF, NAS:MCRB, NAS:AAAP, OTCPK:GENSF, NAS:PRTA, NAS:FPRX, NAS:ACHN, NAS:ALDR, OTCPK:MPSYY, NAS:ONCE, NAS:CXRX, NAS:HALO, NAS:XLRN, NAS:TBPH, OTCPK:BVNRY, OTCPK:PFSCF, NAS:PTLA » details
Traded in other countries:CDG.Germany,
Acorda Therapeutics Inc is a biopharmaceutical company. It is engaged in the identification, development & commercialization of novel therapies for the treatment of neurological disorders.

Acorda Therapeutics Inc was incorporated on March 17, 1995 as a Delaware corporation. It is a biopharmaceutical company, engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug approved by the FDA for the management of spasticity. The Company is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for "Fampyra" and "Kampyra" and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" and "Qutenza" in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.

Ratios

vs
industry
vs
history
P/E(ttm) 78.96
ACOR's P/E(ttm) is ranked lower than
78% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 29.12 vs. ACOR: 78.96 )
Ranked among companies with meaningful P/E(ttm) only.
ACOR' s P/E(ttm) Range Over the Past 10 Years
Min: 6.35  Med: 68.99 Max: 795.63
Current: 78.96
6.35
795.63
PE(NRI) 78.96
ACOR's PE(NRI) is ranked lower than
79% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. ACOR: 78.96 )
Ranked among companies with meaningful PE(NRI) only.
ACOR' s PE(NRI) Range Over the Past 10 Years
Min: 6.35  Med: 68.48 Max: 763.8
Current: 78.96
6.35
763.8
Price/Owner Earnings (ttm) 56.80
ACOR's Price/Owner Earnings (ttm) is ranked lower than
66% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 32.52 vs. ACOR: 56.80 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ACOR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.41  Med: 51.55 Max: 772
Current: 56.8
6.41
772
P/B 1.63
ACOR's P/B is ranked higher than
75% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ACOR: 1.63 )
Ranked among companies with meaningful P/B only.
ACOR' s P/B Range Over the Past 10 Years
Min: 1.63  Med: 4.47 Max: 44.64
Current: 1.63
1.63
44.64
P/S 2.11
ACOR's P/S is ranked higher than
84% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. ACOR: 2.11 )
Ranked among companies with meaningful P/S only.
ACOR' s P/S Range Over the Past 10 Years
Min: 0.12  Med: 4.31 Max: 24.43
Current: 2.11
0.12
24.43
PFCF 21.98
ACOR's PFCF is ranked higher than
60% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 26.54 vs. ACOR: 21.98 )
Ranked among companies with meaningful PFCF only.
ACOR' s PFCF Range Over the Past 10 Years
Min: 10.95  Med: 30.17 Max: 125.73
Current: 21.98
10.95
125.73
POCF 19.63
ACOR's POCF is ranked higher than
55% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 22.98 vs. ACOR: 19.63 )
Ranked among companies with meaningful POCF only.
ACOR' s POCF Range Over the Past 10 Years
Min: 9.57  Med: 27.00 Max: 67.04
Current: 19.63
9.57
67.04
EV-to-EBIT 33.69
ACOR's EV-to-EBIT is ranked lower than
66% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 22.57 vs. ACOR: 33.69 )
Ranked among companies with meaningful EV-to-EBIT only.
ACOR' s EV-to-EBIT Range Over the Past 10 Years
Min: -105.6  Med: 14.40 Max: 89.8
Current: 33.69
-105.6
89.8
EV-to-EBITDA 22.19
ACOR's EV-to-EBITDA is ranked lower than
56% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. ACOR: 22.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACOR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -212.7  Med: 13.20 Max: 66.6
Current: 22.19
-212.7
66.6
Current Ratio 5.18
ACOR's Current Ratio is ranked higher than
55% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ACOR: 5.18 )
Ranked among companies with meaningful Current Ratio only.
ACOR' s Current Ratio Range Over the Past 10 Years
Min: 0.59  Med: 3.77 Max: 8.36
Current: 5.18
0.59
8.36
Quick Ratio 4.81
ACOR's Quick Ratio is ranked higher than
54% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ACOR: 4.81 )
Ranked among companies with meaningful Quick Ratio only.
ACOR' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.42 Max: 8.09
Current: 4.81
0.42
8.09
Days Inventory 162.95
ACOR's Days Inventory is ranked lower than
62% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. ACOR: 162.95 )
Ranked among companies with meaningful Days Inventory only.
ACOR' s Days Inventory Range Over the Past 10 Years
Min: 120  Med: 196.03 Max: 332.51
Current: 162.95
120
332.51
Days Sales Outstanding 29.86
ACOR's Days Sales Outstanding is ranked higher than
76% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. ACOR: 29.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACOR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.31  Med: 34.34 Max: 57.6
Current: 29.86
23.31
57.6
Days Payable 79.80
ACOR's Days Payable is ranked higher than
61% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. ACOR: 79.80 )
Ranked among companies with meaningful Days Payable only.
ACOR' s Days Payable Range Over the Past 10 Years
Min: 55.9  Med: 156.19 Max: 372.18
Current: 79.8
55.9
372.18

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 68.00
ACOR's Price/Net Current Asset Value is ranked lower than
97% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. ACOR: 68.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACOR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.55  Med: 7.25 Max: 323.67
Current: 68
3.55
323.67
Price/Tangible Book 16.11
ACOR's Price/Tangible Book is ranked lower than
88% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. ACOR: 16.11 )
Ranked among companies with meaningful Price/Tangible Book only.
ACOR' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.63  Med: 5.38 Max: 128.61
Current: 16.11
2.63
128.61
Price/Projected FCF 1.06
ACOR's Price/Projected FCF is ranked higher than
87% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. ACOR: 1.06 )
Ranked among companies with meaningful Price/Projected FCF only.
ACOR' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.14  Med: 2.44 Max: 22.07
Current: 1.06
1.14
22.07
Price/Median PS Value 0.49
ACOR's Price/Median PS Value is ranked higher than
79% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. ACOR: 0.49 )
Ranked among companies with meaningful Price/Median PS Value only.
ACOR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 1.00 Max: 5
Current: 0.49
0.04
5
Price/Peter Lynch Fair Value 7.65
ACOR's Price/Peter Lynch Fair Value is ranked lower than
95% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. ACOR: 7.65 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ACOR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.46  Med: 5.76 Max: 8.27
Current: 7.65
1.46
8.27
Price/Graham Number 7.51
ACOR's Price/Graham Number is ranked lower than
85% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 3.09 vs. ACOR: 7.51 )
Ranked among companies with meaningful Price/Graham Number only.
ACOR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.87  Med: 2.63 Max: 8.11
Current: 7.51
0.87
8.11
Earnings Yield (Greenblatt) (%) 3.00
ACOR's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. ACOR: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACOR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 2.70 Max: 7.7
Current: 3
1.1
7.7
Forward Rate of Return (Yacktman) (%) 14.55
ACOR's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.46 vs. ACOR: 14.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ACOR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -121.3  Med: 0.20 Max: 14.5
Current: 14.55
-121.3
14.5

More Statistics

Revenue (TTM) (Mil) $508.7
EPS (TTM) $ 0.31
Beta1.15
Short Percentage of Float17.37%
52-Week Range $23.85 - 43.63
Shares Outstanding (Mil)46.07

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 563 736
EPS ($) -1.34 1.94
EPS w/o NRI ($) -1.34 1.94
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:ACOR

Headlines

Articles On GuruFocus.com
Klarman Profits From Biotie Therapies Buyout Apr 14 2016 
Seth Klarman Buys 763,889 Shares in Drug Development Company Feb 15 2016 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Acorda Therapeutics Inc. Reports Operating Results (10-K) Mar 01 2011 
Steve Cohen Buys ACOR, DPZ, GXDX, NDN, and OREX Feb 07 2011 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 15,000 Shares Dec 03 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 10,905 Shares Dec 03 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 55,000 Shares Aug 09 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
ACORDA THERAPEUTICS INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets,... Jun 27 2016
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events Jun 21 2016
7 Biotech Stocks that are Buys Right Now Jun 17 2016
Acorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : June 13, 2016 Jun 13 2016
Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ... Jun 13 2016
Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : June... Jun 10 2016
ACORDA THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 10 2016
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera... Jun 09 2016
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 09 2016
Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific... Jun 09 2016
Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific... Jun 09 2016
ACORDA THERAPEUTICS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Jun 02 2016
Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference May 31 2016
Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference May 31 2016
Acorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : May 25,... May 25 2016
Acorda Shelves Development of Epilepsy Treatment, Plumiaz May 23 2016
Stocks to Watch: Foot Locker, Deere, Acorda, Campbell Soup, Autodesk May 20 2016
Acorda Dips 2%, Company Says It Will Discontinue Development Of Nasal Spray May 20 2016
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 20 2016
[$$] Acorda to Discontinue Epilepsy Drug Development May 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)